Wegovy Reduces Heavy Symptom Burden of Obesity-Related Heart Failure
(MedPage Today) -- AMSTERDAM -- Semaglutide 2.4 mg (Wegovy) led to clinically meaningful reductions in symptoms and weight among patients with obesity and heart failure with preserved ejection fraction (HFpEF), the STEP-HFpEF trial showed.
While...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news
More News: Cardiology | Eating Disorders & Weight Management | Heart | Heart Failure | Obesity | Urology & Nephrology